Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aytu BioScience, Inc.

1.11
+0.06005.71%
Post-market: 1.110.00000.00%17:15 EDT
Volume:30.96K
Turnover:33.40K
Market Cap:6.85M
PE:-0.58
High:1.11
Open:1.06
Low:1.05
Close:1.05
Loading ...

Company Profile

Company Name:
Aytu BioScience, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
Denver Corporate Center III,Suite 920,7900 East Union Avenue,Denver,Colorado,United States
Zip Code:
80237
Fax:
- -
Introduction:
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Directors

Name
Position
Joshua R. Disbrow
Chairman and Chief Executive Officer
John A. Donofrio, Jr.
Lead Independent Director
Abhinav Jian
Director
Carl C. Dockery
Director
Vivian H. Liu
Director

Shareholders

Name
Position
Joshua R. Disbrow
Chairman and Chief Executive Officer
Mark K. Oki
Chief Financial Officer, Corporate Secretary and Treasurer
Greg Pyszczymuka
Chief Commercial Officer
Jarrett T. Disbrow
Chief Business Officer